The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
- Published In:
- BMC infectious diseases, 16, 488 (2016)
- Authors:
- Liu, Fang, Wang, Hong-Mei, Wang, Tiansheng, Zhang, Ya-Mei, Zhu, Xi
- Database ID:
- RPEP-03021
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03021APA
Liu, Fang; Wang, Hong-Mei; Wang, Tiansheng; Zhang, Ya-Mei; Zhu, Xi. (2016). The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.. BMC infectious diseases, 16, 488. https://doi.org/10.1186/s12879-016-1823-5
MLA
Liu, Fang, et al. "The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.." BMC infectious diseases, 2016. https://doi.org/10.1186/s12879-016-1823-5
RethinkPeptides
RethinkPeptides Research Database. "The efficacy of thymosin α1 as immunomodulatory treatment fo..." RPEP-03021. Retrieved from https://rethinkpeptides.com/research/liu-2016-the-efficacy-of-thymosin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.